After scrapping a Biden-era plan to cover obesity drugs in early 2025, the Trump administration reversed course: it struck deals with Novo Nordisk and Eli Lilly in November 2025 to cut GLP-1 prices, and a voluntary Medicare demonstration begins July 1, 2026 that lets participating drug plans cover GLP-1s for weight loss with a $50 monthly copay
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial
Participants consumed excess sodium, saturated fat, and calories
Together, these peptides might improve circulation, reduce inflammation, and speed up cellular responses that allow injured tissues to develop new structures more efficiently
The Wolverine Stack pairs both peptides in a single research protocol so local vessel formation and systemic cell recruitment can be observed together a preclinical hypothesis, not a proven human treatment
Hagedorn, J